Home > Osi Pharmaceuticals Salary

Osi Pharmaceuticals Salary

  • 26
  • 77
  • 19
Osi Pharmaceuticals average salary is $150,000, median salary is $150,000 with a salary range from $150,000 to $150,000.
Osi Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. Osi Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
150,000
Average
150,000
Median
150,000
High
150,000
Total 1 Osi Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Director 150,000-150,000 New York, NY, 10001 2012 Osi Pharmaceuticals Director Salaries (1)
Osi Pharmaceuticals New York, NY Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Osi Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Osi Pharmaceuticals Jobs
See more Osi Pharmaceuticals Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Patents information
1235

All Patents

289

Grant Patents

755

Patents Pending

193

Patents Families

More Recent
Osi Pharmaceuticals... Information
  • OSI Pharmaceuticals, Inc.
  • Industry: BioTech/Drugs
  • City: Melville, NY
  • OSI Pharmaceuticals is a leading biotechnology company primarily focused on the discovery, development and commercialization of innovative products for the treatment of cancer. OSI has built a pipeline of discovery programs and drug candidates addressing major, unmet medical needs in cancer and selected opportunities, including diabetes, arising from the Company's extensive drug discovery research programs that represent significant commercial opportunities outside of cancer. OSI's most advanced drug candidate, Tarceva(TM) (OSI-774), a small molecule inhibitor of the EGFR gene, is currently in Phase III clinical trials for lung and pancreatic cancers.